SGLT-2 Inhibitors Reduce Dementia Risk vs DPP-4 Inhibitors
Patients with type 2 diabetes treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitors have a significantly lower risk of developing dementia and Alzheimer's disease than those receiving dipeptidyl peptidase-4 (DPP-4) inhibitors, with the …